Skip to main content
Premium Trial:

Request an Annual Quote

Verisante Inks Deal for $2.8M in Funding and Chinese Distribution

Premium

NEW YORK (GenomeWeb) – Verisante said this week that it has closed a non-brokered private placement of 2 million common shares at a price of $.15 per share, raising a total of $300,000.

The placement comes in conjunction with the company's agreement with an unnamed strategic partner for exclusive marketing and sales rights to its Raman spectroscopy-based Core cancer detection system and ClearVu endoscopic camera.

This agreement is contingent on Verisante receiving an additional $2.5 million in investment by the end of September 2014. That private placement will be for common shares discounted below the market price at a rate of no greater than 15 percent.

Under the agreement, the unnamed partner will fund the China Food & Drug Administration approval process for products beginning with the Core for lung cancer, including additional clinical trials if needed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.